Market Overview

I think you’ll love what you hear,
what you’ll see and the opportunities
that will be set before you.
- Jon Najarian
GET TICKETS

Aratana Therapeutics Appoints Rhonda Hellums Chief Financial Officer

Share:

LEAWOOD, Kan., Feb. 4, 2019 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ:PETX), a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats, today announced the appointment of Rhonda Hellums as Chief Financial Officer and Treasurer of Aratana effective February 1, 2019. Hellums will transition into the CFO role from her position as Vice President of Finance and will succeed Craig Tooman, who was recently appointed the Company's President and Chief Effective Officer.

Aratana Therapeutics logo

"Rhonda has extensive financial expertise and a strong track record of building businesses," stated Craig Tooman, President and Chief Executive Officer of Aratana. "She is a cross-functional collaborator and in her career, Rhonda has been a vital part of driving growth at many successful companies, including Genzyme, KCI, ILEX Oncology, Enzon and KPMG. I believe Rhonda is the ideal fit for CFO as we focus on achieving greater results for all our stakeholders."

Rhonda Hellums has more than 20 years of experience in finance and operations, specifically bringing a deep skillset in strategic planning, systems implementation, business development and investor relations. Prior to her role at Aratana, Hellums served as Director of Global Finance at Kinetic Concepts, Inc. (KCI), a global medical device company with more than $1 billion in revenues and 5,000 employees, where she was responsible for global finance functions, portfolio valuation and planning. Hellums served as Vice President of Finance for Enzon Pharmaceuticals where she oversaw $180 million in investments, investor relations, as well as coordinated key components of the $300 million sale of Enzon's specialty pharmaceutical business. She worked at ILEX Oncology, Inc. as the Director of Finance and Strategic Planning when it was acquired by Genzyme Corporation. Subsequently, Genzyme named her Director of Finance, Alliance and Strategic Planning. Early in her career, Hellums was a management consultant for KPMG, LLC. and client EG&G, Inc., a division of URS Corporation, hired her to serve as their Division Controller. Hellums earned her M.B.A. from the University of Texas at San Antonio and a B.A. in Accounting and Information Systems from the University of Texas at San Antonio.

About Aratana Therapeutics
Aratana Therapeutics is a pet therapeutics company focused on developing and commercializing innovative therapeutics for dogs and cats. As a pioneer in pet therapeutics, Aratana's mission is to deliver safe and effective therapeutics that elevate the standard of care in veterinary medicine. We work with companion animal veterinarians to bring new therapeutics to market that support the needs of pets and their owners. For more information, please visit www.aratana.com.

Contacts
For investor inquires:
ir@aratana.com 
(913) 353-1026

For media inquiries:
Rachel Reiff
media@aratana.com
(913) 353-1050

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/aratana-therapeutics-appoints-rhonda-hellums-chief-financial-officer-300788797.html

SOURCE Aratana Therapeutics

View Comments and Join the Discussion!